3 results
The primary objective of this pilot study is to evaluate the effects of 6 months of recombinant human IGF-I (rhIGF-I) treatment on the body composition.The secondary objective is to assess the effects of the treatment on the liver function,…
The study aims to limit the use of anthracyclines and to reduce the dose of ATRA. Another aim is to stratify treatment by risk group: standard risk - WBC <10 x 109/l : high risk - WBC >=10 x 109/l. Furthermore this study aims to…
The primary objective of the study will be to evaluate two low doses of a single intracoronary injection of rhIGF-1 compared with saline placebo on global LVEF by cardiac MRI and for safety (hypoglycaemia) in select subjects with STEMI and severe…